Reply  by Kulik, Thomas J. et al.
of ICU patients, including pediatric patients. Published guidelines
for general pediatric ICUs, endorsed by the American College of
Critical Care Medicine, offer similar recommendations (6). In
addition, the specialty boards in medicine, surgery, anesthesia, and
pediatrics have each established pathways for certification in
critical care medicine. We submit that critically ill children in a
cardiac ICU deserve the same collaborative multidisciplinary
model of clinical care.
We acknowledge that cardiologists who complete the abbrevi-
ated critical care rotations outlined in the American College of
Cardiology Foundation/American Heart Association/American
Academy of Pediatrics (ACCF/AHA/AAP) document will have
added critical care skills, but this additional clinical experience does
not transform a cardiologist into an “intensivist” any more than a
few clinical months of cardiology training could convert an
“intensivist” into a “cardiologist.” The training for any physician
who wishes to practice pediatric critical care medicine should not
be fast-tracked. The specific areas of proposed knowledge and
competence outlined by Beekman et al. (1) are similar to the
curriculum document of a full critical care medicine fellowship,
including but not limited to knowledge regarding management of
increased intracranial pressure, coagulation disorders, advanced
ventilator management techniques, renal failure management, and
nutrition support. It takes a full three years of a critical care
medicine fellowship to begin to master these concepts; therefore,
we believe nine months of additional clinical training beyond a
standard cardiology fellowship is insufficient to produce clinicians
to fulfill the “intensivist” role in the cardiac ICU.
In sum, all critically ill children should be cared for by a team of
clinicians, including but not limited to board-certified critical care
medicine specialists. Critically ill children in the cardiac ICU
deserve the same level of expertise. The physician who wishes to
fulfill both the “cardiologist” and the “intensivist” role in the
cardiac ICU should follow the five-year path outlined by the
American Board of Pediatrics for dual certification in both
cardiology and critical care medicine. There can be no shortcuts on
this very important issue in the care of critically ill children. We
advocate a model of care that incorporates all relevant clinical
experts. We believe that such a model is most consistent with the
highest quality critical care practice.
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REPLY
Dr. Baden and colleagues argue that our advanced practice in
pediatric cardiac critical care training program (1) is insufficient to
produce independent cardiac intensivists, and that cardiac patients
in the intensive care unit (ICU) must be cared for by board-
certified critical care medicine (CCM) specialists. After making
the unassailable observation that care of critically ill patients
requires multidisciplinary collaboration, they assert the “well-
established concept” that this team must be led, or co-led, by
someone certified in CCM. Whereas this notion may be congenial
to pediatric intensivists, the references they cite (2–6) suggest only
that practitioners with special skills best care for such patients;
these studies provide no data to indicate what type of program is
required to train same.
Indeed, at issue here is not whether special training is necessary,
but rather how much. Pediatric CCM specifies three years (18
clinical months), but other disciplines require significantly less. Dr.
Baden and colleagues point out— by way of showing good
examples—that internal medicine, surgery, and anesthesia have
pathways for certification in CCM. Indeed, and it turns out that
their critical care training programs are quantitatively essentially
identical to ours (7–9). Internal medicine requires 11 months of
clinical training in critical care beyond subspecialty training (the
latter taking as few as two years), but clinical training experience in
CCM that occurs during subspecialty training may be applied to
the requirements for both subspecialty and critical care training.
Dual certification in CCM and cardiovascular medicine is possible
with only a total of 30 months of combined clinical training in
cardiovascular medicine and CCM. Anesthesia requires 12 months
(beyond core anesthesia training) of critical care training, only nine
of which must be clinical. For surgery, 12 months of critical care
training are required, but up to 25% of that time may be spent in
direct operative care of patients. Our training guidelines specify at
least nine months of clinical cardiac intensive care training (beyond
the three years of pediatric cardiology training), which is clearly
commensurate with that required for critical care certification for
these subspecialties.
Pediatric CCM opts for 1.5 years of clinical training, perhaps
because pediatric CCM trainees have only three years of postdoc-
toral training as preparation. Our guidelines, however, apply to
board-eligible/-certified pediatric cardiologists who, with six years
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of postdoctoral training, are comparable to trainees in the special-
ties noted above.
We believe that efforts to gerrymander qualification boundaries
to exclude able practitioners from practice work against, rather
than foster, a culture of multidisciplinary collaborative care. We
who developed these guidelines—including multiple physicians
with pediatric CCM certification—did not do so hoping to attain
a self-bestowed hegemony for deciding what constitutes acceptable
cardiac intensive care training. Rather, we called on many years of
experience in an effort to formulate guidelines to prepare a
pediatric cardiologist to be expert in managing critically ill cardiac
patients, recognizing that various disciplines, such as pediatric
CCM, will employ other training models. No doubt cardiac
intensivists will benefit from consultation with CCM colleagues, as
will also happen in reverse—a robust culture of multidisciplinary
care being essential regardless of the pathway chosen to become a
cardiac intensivist.
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Diagnosis and Management
of Chronic Heart Failure
The American College of Cardiology/American Heart Association
(ACC/AHA) 2005 guideline update for the diagnosis and man-
agement of chronic heart failure in the adult recently published
in the Journal (1) states that the addition of a combination of
isosorbide dinitrate and hydralazine to conventional therapy is
strongly recommended (class IIa) with a high level of evidence
(level A) for patients who have persistent symptoms without
making a distinction on the patient’s race.
Although in the complete version of the guideline (available on
JACC ’s Web site) it is pointed out that, based on the results of the
A-HeFT trial (2), there is not enough evidence to extrapolate the
results obtained in black people to the general population; neither the
abbreviated nor the complete guideline includes this limitation in the
recommendations. To avoid misunderstandings, we believe that this
fact should explicitly be reported in both the shortened and complete
versions of the guideline when the recommendation of adding
isosorbide dinitrate and hydralazine to conventional therapy is made.
As pointed out above, the recommendation of adding isosorbide
dinitrate and hydralazine is based on only one controlled, random-
ized trial (2). It is surprising that the effect of the addition of an
angiotensin receptor blocker (ARB) in symptomatic patients who
are already being treated with conventional therapy, also evaluated
only in one controlled, randomized trial (3), has been considered as
a class IIb recommendation with a level of evidence B despite the
important benefits showed in the CHARM-Added trial (3).
An additional comment concerns the use of nebivolol in heart
failure. In the 2005 guideline there is no mention of nebivolol in
heart failure treatment. Nebivolol, a beta1 selective blocker with
vasodilating properties due to nitric oxide modulation, was tested
in the SENIORS trial (4) and extended the evidence of beta-
blockers’ benefits to a broad population of elderly patients with
heart failure. The effect of nebivolol has been tested only in one
trial involving elderly patients, but if other drug therapies are
recommended based on one-trial evidence we believe that nebivo-
lol should, at least, be mentioned as an option in elderly patients
with heart failure.
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